Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

Osteoporosis International

Volumn 14, Issue 12, 2003, Pages 1001-1006

  Fogelman, I ^a   Blake, G M ^a   Blamey, R ^b   Palmer, M ^c   Sauerbrei, W ^a   Schumacher, M ^d   Serin, D ^e   Stewart, A ^f   Wilpshaar, W ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Nottingham   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Department of Radiation Therapy   (France)

^f CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Bone mineral density; Goserelin; Node positive early breast cancer; Premenopausal; ZEBRA

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; METHOTREXATE;

ADULT; AMENORRHEA; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; FEMALE; FEMUR NECK; GENERAL CONDITION IMPROVEMENT; HUMAN; LUMBAR SPINE; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOLYSIS; OVARY FUNCTION; OVULATION INHIBITION; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR NECK; FLUOROURACIL; GOSERELIN; HUMANS; LUMBAR VERTEBRAE; METHOTREXATE; PREMENOPAUSE;

EID: 5444276106     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-003-1508-y     Document Type: Article

References (29)

1. Del Mastro L, Venturini M, Sertoli MR, Rosso R (1997) Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43:183-190
2. Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsh A, Rudenstam CM et al. (1998) Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640
3. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M et al. (2002) Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study. J Clin Oncol 20:4628-4635
4. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P et al. (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727
5. Jakesz R, Hausmaninger H, Samonigg H et al. (2001) Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and -negative patients with hormone-responsive breast cancer. Breast 10:S10 (abstract S26)
6. Davidson N, O'Neill A, Vukov A, Osborne S, Martino D, White M.D (1999) Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup trial. Proc ASCO 18:67a (abstract 249)
7. Baum M, Houghton J, Odling-Smee W et al. (2001) Adjuvant Zoladex in premenopausal patients with early breast cancer: results from the ZIPP trial. Breast 10:S32-S33 (abstract P64)
8. de Haes H and the ZEBRA Trialists Group (2000) Comparison of quality of life in pre/perimenopausal women treated with Zoladex or CMF as adjuvant therapy for the management of node-positive early breast cancer: results from the ZEBRA study. Breast Pharmacokinet 39:27-48
9. Olschewski M, de Haes H (2001) The ZEBRA study: early benefits in quality of life in goserelin-treated vs CMF-treated pre/perimenopausal patients with node-positive early breast cancer. Eur J Cancer 37:S40 (abstract Q115)
10. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T et al. (2002) Randomized adjuvant trial of tamoxifen plus goserelin versus cyclophosphamide, methotrexate and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. J Clin Oncol 20:4621-4627
11. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Aldrighetti D et al. (2001) CMF vs tamoxifen (TAM) plus ovarian suppression (OS) as adjuvant treatment of ER-positive (ER+) pre/perimenopausal breast cancer (BCA) patients. Breast 10:S32 (abstract P62)
12. Trevisan C, Ortolani S, Bianchi ML, Caraceni MP, Ulivieri FM, Gandolini G, Polli EE (1991) Age, time since menopause, and body parameters as determinants of female spinal bone mass: a mathematical model. Calcif Tiss Int 49:1-5
13. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK et al. (1993) Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341:72-75
14. Tannirandorn P, Epstein S (2000) Drug-induced bone loss. Osteoporos Int 11:637-659
15. Fogelman I (1996) The effects of estrogen deficiency on the skeleton and its prevention. Br J Obstet Gynaecol 103 (suppl 14):5-9
16. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347
17. Melton LJ, Thamer M, Ray NF, Chan JK, Chesnut CH, Einhorn TA et al. (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16-23
18. Peterson JA (2001) Osteoporosis overview. Geriatr Nurs 22:17-21
19. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410
20. Steiger P (1995) Standardization of spine BMD measurements. J Bone Miner Res 10:1602-1603
21. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K et al. (1994) Universal standardization for dual X-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 9:1503-1514
22. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308-310
23. Headley JA, Theriault RL, LeBlanc AD, Vassilopoulou-Sellin R, Hortobagyi GN (1998) Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16:6-11
24. Delmas PD, Fontana A (1998) Bone loss induced by cancer treatment and its management. Eur J Cancer 34:260-262
25. Fogelman I (1992) Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 57:715-724
26. Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, Melis GB (1996) Spontaneous reversibility of bone loss induced by gonadotropin- releasing hormone analog treatment. Fertil Steril 65:707-710
27. Taga M, Minaguchi H (1996) Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 75:162-165
28. Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A et al. (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708
29. Namer M, Jonat W, Kaufmann M, Blamey R, Cuzick J, Fogelman I et al. (2002) Survival data from the ZEBRA study. Ann Oncol 13 (suppl 5):38 (abstract 135P)